Project Grant R43AI152774

Federal Project Grant Award Summary Tendel Therapies Inc. received a $999,991 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 13, 2025, with a completion date of July 31, 2028. The award supports the development and optimization of BSAB-98, a bispecific antibody (BSAB) therapeutic agent designed to deplete CCR5-expressing cells that form a critical component of the HIV...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Missouri System a $538,501 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel RNA aptamer tools for studying HIV capsid protein (CA) structure, function, and protein-host interactions. The award, effective April 1, 2026 through March 31, 2031, supports research aimed at addressing critical gaps in understanding CA's role in HIV replication events,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

Federal Grant Award Summary Emmune Inc. received a $1.84 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded June 17, 2025, with a completion date of May 31, 2026. The company is developing a non-viral gene therapy platform utilizing ECD4-IG, a therapeutic protein constructed from parts of HIV's primary receptor (CD4) and coreceptor (CCR5), to deliver long-term HIV...

Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $232,558 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 13, 2026, with completion targeted for March 31, 2028. The grant funds research and development of an innovative gene therapy approach utilizing adeno-associated virus (AAV)-delivered meganucleases to achieve durable control of genital...

This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program seeks to develop a new class of gene therapies that can be delivered more safely, cost-effectively, and at scale for a wide range of serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Florida a $1,016,887 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 6, 2025, with a completion date of July 31, 2030. This grant supports research to develop novel HIV-1 Tat protein-degrading molecules as therapeutic candidates to complement antiretroviral therapy and advance the "block-and-lock" functional cure strategy. The research addresses...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...

Federal Grant Award Summary The National Institute on Drug Abuse awarded J. David Gladstone Institutes a $1,343,271 Project Grant (CFDA 93.279, Drug Use and Addiction Research Programs) effective May 15, 2025, through March 31, 2030, to develop targeted small molecule recruitment strategies for suppressing the HIV transcriptionally active reservoir in individuals with substance use disorder (SUD). The research addresses a critical gap in antiretroviral therapy (ART), which fails to target latent...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $718,637 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 24, 2026, with a completion date of January 31, 2031. This research initiative focuses on evaluating camptothecin analogs as potential "block and lock" therapeutic agents to suppress HIV (human immunodeficiency virus)...